Eye care drugmaker Harrow swings to Q3 profit

Reuters11-11

Eye care drugmaker Harrow swings to Q3 profit

Overview

Harrow Q3 revenue rises 45% yr/yr but misses analyst expectations
Company reports GAAP net income of $1.0 mln for Q3 2025
Adjusted EBITDA for Q3 2025 reaches $22.7 mln

Outlook

Company expects VEVYE to gain preferred product status on new formularies by Jan 2026
Company anticipates sustained growth with strategic initiatives and coverage wins for VEVYE

Result Drivers

PRODUCT PERFORMANCE - Strong performance from VEVYE and IHEEZO drove revenue growth, per CEO Mark L. Baum
COVERAGE EXPANSION - New coverage agreements for VEVYE with major payers expected to enhance market access

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Miss	$71.60 mln	$73.70 mln (8 Analysts)
Q3 Core EPS		$0.33
Q3 Gross Margin		75.00%
Q3 Core Gross Margin		81.00%

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Harrow Inc is $64.40, about 47.3% above its November 7 closing price of $33.93
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 33 three months ago

Press Release: ID:nGNX2h8FX3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582945388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 05:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582945388","market":"us","top_or_hot":-1,"title":"Eye care drugmaker Harrow swings to Q3 profit","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Eye care drugmaker Harrow swings to Q3 profit</title></head><body><p><span>Overview</span></p><ul><li><p>Harrow Q3 revenue rises 45% yr/yr but misses analyst expectations</p></li><li><p>Company reports GAAP net income of $1.0 mln for Q3 2025 </p></li><li><p>Adjusted EBITDA for Q3 2025 reaches $22.7 mln</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects VEVYE to gain preferred product status on new formularies by Jan 2026</p></li><li><p>Company anticipates sustained growth with strategic initiatives and coverage wins for VEVYE</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRODUCT PERFORMANCE - Strong performance from VEVYE and IHEEZO drove revenue growth, per CEO Mark L. Baum</p></li><li><p>COVERAGE EXPANSION - New coverage agreements for VEVYE with major payers expected to enhance market access</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$71.60 mln</p></td><td><p>$73.70 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Core EPS</p></td><td></td><td><p>$0.33</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>75.00%</p></td><td></td></tr><tr><td><p>Q3 Core Gross Margin</p></td><td></td><td><p>81.00%</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Harrow Inc is $64.40, about 47.3% above its November 7 closing price of $33.93</p></li><li><p>The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 33 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX2h8FX3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eye care drugmaker Harrow swings to Q3 profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEye care drugmaker Harrow swings to Q3 profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-11 05:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Eye care drugmaker Harrow swings to Q3 profit</title></head><body><p><span>Overview</span></p><ul><li><p>Harrow Q3 revenue rises 45% yr/yr but misses analyst expectations</p></li><li><p>Company reports GAAP net income of $1.0 mln for Q3 2025 </p></li><li><p>Adjusted EBITDA for Q3 2025 reaches $22.7 mln</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects VEVYE to gain preferred product status on new formularies by Jan 2026</p></li><li><p>Company anticipates sustained growth with strategic initiatives and coverage wins for VEVYE</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRODUCT PERFORMANCE - Strong performance from VEVYE and IHEEZO drove revenue growth, per CEO Mark L. Baum</p></li><li><p>COVERAGE EXPANSION - New coverage agreements for VEVYE with major payers expected to enhance market access</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$71.60 mln</p></td><td><p>$73.70 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Core EPS</p></td><td></td><td><p>$0.33</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>75.00%</p></td><td></td></tr><tr><td><p>Q3 Core Gross Margin</p></td><td></td><td><p>81.00%</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Harrow Inc is $64.40, about 47.3% above its November 7 closing price of $33.93</p></li><li><p>The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 33 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX2h8FX3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM139:1","article_id":"2582945388","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582945388","pubTimestamp":1762809811,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Eye care drugmaker Harrow swings to Q3 profitOverviewHarrow Q3 revenue rises 45% yr/yr but misses analyst expectationsCompany reports GAAP net income of $1.0 mln for Q3 2025 Adjusted EBITDA for Q3 202","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc","BK4557":"大麻股","BK4007":"制药"},"translate_title":"眼部护理制药商哈罗公司第三季度实现盈利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":0.9},"content_text":"Eye care drugmaker Harrow swings to Q3 profitOverviewHarrow Q3 revenue rises 45% yr/yr but misses analyst expectationsCompany reports GAAP net income of $1.0 mln for Q3 2025 Adjusted EBITDA for Q3 2025 reaches $22.7 mlnOutlookCompany expects VEVYE to gain preferred product status on new formularies by Jan 2026Company anticipates sustained growth with strategic initiatives and coverage wins for VEVYEResult DriversPRODUCT PERFORMANCE - Strong performance from VEVYE and IHEEZO drove revenue growth, per CEO Mark L. BaumCOVERAGE EXPANSION - New coverage agreements for VEVYE with major payers expected to enhance market accessKey DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueMiss$71.60 mln$73.70 mln (8 Analysts)Q3 Core EPS$0.33Q3 Gross Margin75.00%Q3 Core Gross Margin81.00%Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Harrow Inc is $64.40, about 47.3% above its November 7 closing price of $33.93The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 33 three months agoPress Release: ID:nGNX2h8FX3For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582945388","isCrawlerRequest":true}